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ABSTRACT: (200 words) 
The high mortality rate associated with pancreatic ductal adenocarcinoma (PDAC) is in part due 
to lack of effective therapy for this highly chemoresistant tumor. Cancer stem cells, a subset of 
cancer cells responsible for tumor initiation and metastasis, are not targeted by conventional 
cytotoxic agents, which renders the identification of factors that facilitate cancer stem cell 
activation useful in defining targetable mechanisms. We determined that bioactive sphingolipid 
induced migration of pancreatic cancer stem cells (PCSC) and signaling was specific to 
ceramide-1-phosphate (C1P). Furthermore, PDAC cells were identified as a rich source of C1P. 
Importantly, PDAC cells express the C1P converting enzyme ceramide kinase (CerK), secrete 
C1P-containing extracellular vesicles that mediate PCSC migration, and when co-injected with 
PCSC reduce animal survival in a PDAC peritoneal dissemination model. Our findings suggest 
that PDAC secrete C1P-containing extracellular vesicles as a means of recruiting PCSC to 
sustain tumor growth therefore making C1P release a mechanism that could facilitate tumor 
progression.  
 
Highlights:  
- PDAC are a source of bioactive sphingolipid C1P 
- PDAC secrete C1P-containing vesicles recruit PCSC 
- Uptake of PDAC secreted C1P-vesicles in a peri-nuclear region of PCSC  
- PDAC and PCSC co-injection reduces animal survival.  
 
  
1. Introduction: (5,000 words) 
Pancreatic cancer, the third leading cause of death in the United States when both genders are 
combined, is expected to become the second-leading cause of death by 2030 (1). Asymptomatic 
during early stages, detection of pancreatic cancers remains a challenge as the majority of cases 
are identified following invasion of adjacent lymph nodes or metastasis to distant sites. 
Accounting for ~85% of pancreatic cancers, pancreatic ductal adenocarcinoma (PDAC) is an 
aggressive tumor of multiple cell lineages composed of complex stromal elements, epithelial 
adenocarcinoma cells, and cancer stem cells (CSC); it is often fatal with a 5-year survival rate of 
less than 6% (2). Despite more intense drug regimens, there remains a large gap in improving 
overall survival of patients with pancreatic cancers due to marked resistance to conventional 
chemotherapy, rapid growth and progression and high probability of recurrence after resection of 
apparently localized disease. Identification of additional therapeutic targets is essential to further 
enhance a targeted-cytotoxic combination strategy for advanced PDAC.  
 
Cancer stem cells, a subset of cancer cells responsible for tumor initiation and metastasis, are not 
the primary target of conventional chemotherapy. Recently, lipid signaling has been shown to be 
an important element of the stem cell niche (3) and may represent a novel targeting mechanism 
of inhibiting CSC migration and proliferation. Bioactive lipids, sphingolipids, are structural 
components of eukaryotic cell membranes that have key roles in cellular signaling and 
membrane trafficking. In response to inflammation, cells release bioactive lipids that function 
locally to mediate local apoptosis, cell growth, and differentiation(4). One such lipid is ceramide, 
which promotes apoptosis and can induce cell cycle arrest. Ceramide-1-phosphate (C1P), its 
direct metabolite through phosphorylation by the enzyme ceramide kinase (CerK), has opposite 
effects as it has been shown to increase cell proliferation, serve as an anti-inflammatory signal 
and facilitate cell evasion of apoptosis(5). Found in extracellular fluid, C1P plays a critical role 
as a chemoattractant in trafficking of normal and stem cell populations(5), however its receptor 
remains unknown. While recent studies have focused on C1P’s impact on hematopoietic CSC 
migration and proliferation, mechanistically C1P’s impact in solid tumors such as pancreatic 
cancer is poorly understood. In this study, we determined that sphingolipid activation of 
pancreatic CSC (PCSC) migration and adhesion is C1P specific and selective for PCSC as 
PDAC cells are unaffected. Reduction in animal survival using an established peritoneal 
dissemination model when PCSC are co-injected with PDAC cells as well as enhanced PCSC 
migration in response to PDAC-conditioned medium supports PDAC-facilitated PCSC activation. 
Localization of both C1P-containing extracellular vesicles in PDAC conditioned medium and 
labeled C1P to the peri-nuclear region suggest that PDAC cells promote PCSC migration and 
activation through release of C1P-containing extracellular vesicles. 
  
2. Materials and Methods: 
Reagents: Lipids and Topfluor-lipids were acquired from Avanti Polar Lipids (Alabaster, AL). 
C16 Ceramide-1-Phosphate (d18:1/16:0) (Avanti Polar Lipids, Inc. #860533) or C16 Ceramide  
(d18:1/16:0) (Avanti Polar Lipids, Inc. #860516) initially were dissolved in chloroform before 
aliquoting and drying under nitrogen stream. Lipids were reconstituted in 98:2 ethanol:dodecane 
solution at 100 mM solution resulting in the stock solution having a dodecane/C1P ratio  1 that 
is well below the noted toxicity range of dodecane (6) and diluted as noted below. Fibronectin 
human protein, collagen I rat protein, and laminin mouse protein (natural) were obtained from 
Life Technologies (St. Petersburg, FL). 
Lipidomics analysis: Cells were counted, rinsed in PBS, pelleted and frozen at minus 80 degrees 
Celsius. Equal cell numbers were were analyzed at the Medical University of South Carolina 
(MUSC) core facility using a MRM transition from molecular weight to 264 amu (sphingoid 
base backbone) along with chromatographic separation. Standards were utilized for each 
measurement and extraction was performed using an isopropanol/ethyl acetate extraction method 
followed by lipid extraction and analysis by HPLC (7, 8). C1P was normalized to total cell 
number and samples obtained at different passages and on different days. 
Cell Culture: Human Pancreatic Cancer Stem Cells purchased from Celprogen (Torrance, CA), 
grown in Celprogen Complete Growth Medium at 37°C in a humidified 5% CO2 atmosphere and 
used between passages 3-9 with Trypsin/EDTA (Celprogen) and split at a 1:3 ratio. Cell 
phenotype was confirmed prior to use. PDAC Human AsPC-1, CFPAC (human pancreatic ductal 
adenocarcinoma derived from metastatic origin), and Panc-1 (human pancreatic duct epithelioid 
carcinoma) cells were obtained from ATCC. AsPC-1 cells were grown in RPMI 1640 medium 
  
(Sigma Chemical, St Louis, MO) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin in a humidified 5% CO2 atmosphere. Panc-1 and CFPAC cells were 
grown in DMEM  (HyClone, Logan, UT) supplemented with 10% FBS and 1% 
penicillin/streptomycin in a humidified 5% CO2 atmosphere. 
Conditioned Medium: Some studies were performed using CFPAC-conditioned medium 
obtained by collecting DMEM off of 80% confluent CFPAC cells after a 24-hour incubation 
period. Conditioned medium was filtered with a 0.22µm filter (Jet Biofil, Elgin, IL) and mixed 
1:1 with fresh DMEM medium for replenishment. For control, un-conditioned CFPAC medium 
(CFPAC Medium) was used (9, 10).  
Hanging Drops: A 3D hanging drop model was used to assess migration via compaction using 
three dimensional cell spheroids (11-16). Cells were suspended in their respective growth media 
with vehicle or treatment at a concentration of 2.5x106 cells/ml for PCSCs and 1.5x106 cells/ml 
for CFPAC cells.  Hanging drops of 12.5μl (31,250 PCSC cells/HD and 18,750 CFPAC 
cells/HD) were suspended over PBS on the lids of 60 mm Petri dishes. Compaction of cells 
during self-assembly for 48 hours was assessed in phase contrast images by outlining the cellular 
mass and measurement of the entire outline of the HD in pixel number as previously described 
(17). 
Scratch Assay: Cell migration was assessed using scratch tests on 12 well ‘expansion’ plates 
obtained from Celprogen. Cells were plated at a density of 2.2 x 105 cells per well and allowed to 
seed for 24 hours, after which a confluent monolayer formed. Each well was scratched with a 
pipette tip and washed twice with PBS. Wells were then treated with 3 or 10 µM ceramide 1-
phosphate, ceramide, or vehicle (98:2 ethanol:dodecane) dilutions from an original 100 mM 
  
stock. Cells were imaged using IX81 Olympus Spinning Confocal microscope images captured 
with a Hamamatsu Orca-ER Digital camera. Scratches were imaged at 0 hours and 24 hours, and 
the scratch area was measured using (CellSens software) to determine percent closure.  
Co-culture Scratch Test: 0.12 x 106 cells of CFPAC and PCSCs were grown in 6.5mm transwells 
(VWR, Radnor, PA) for 24 hours. Concurrently, 2.2 x 106 PCSCs were plated onto 12-well 
plates and allowed to seed for 24 hours. 12-well plates were then scratched, washed 2x with PBS, 
and new medium was added with treatment or vehicle. Scratches were imaged and transwells 
containing either CFPACs or PCSCs were added to each well. PCSC transwells were added to 
vehicle and C1P treated wells, whereas CFPAC transwells were added to the CFPAC condition. 
After 24 hours transwells were removed and scratches were imaged and assessed for percent 
closure.  
Adhesion Assay: Non-tissue culture treated 96-well plates (Sigma-Aldrich) were coated with 1, 3, 
or 10 µg of laminin (LA), collagen (type I) (CL), or fibronectin (FN). ECM proteins dissolved in 
CAPS buffer (carbonate-bicarbonate buffer) for plate coating. Some wells were treated with 
10µM ceramide or C1P. Treated plates were then incubated at 4oC overnight to allow for coating. 
Coating treatment was removed and wells were washed three times with PBS before adding cells 
(0.4 x 104 cells per well). Plates were treated with 1% BSA for one hour, then washed three 
times. The assay was performed with PCSCs and CFPAC cells. CFPAC cells were allowed to 
adhere at 37°C in a humidified 5% CO2 atmosphere for 2.5-4 hours, whereas PCSCs were 
allowed to adhere for 1-2 hours, depending on ECM type. After cell adherence, wells were 
washed twice and then treated with crystal violet with standard protocol. Crystal violet was 
solubilized using 10% (v/v) acetic acid. Plate was read at 570 nm.  
  
Vesicle isolation: Cells grown to 70% confluence were rinsed with PBS and incubated with 
serum-free (SF) complete medium for 24 hours. Supernatant was collected and added drop wise 
into an ultracentrifuge tube containing STE with 20% sucrose. Cellular debris was removed by 
spinning the cells down for 30 min at 10,000 g. The supernatant was transferred to a new tube 
and spun for 90 min at 100,000g. Vesicles were resuspended in PBS. Some were surface labeled 
with PKH26 red fluorescent dye (Sigma) for visualization while others were sent for lipidomic 
analysis (MUSC). All samples were normalized to total phosphate (Pi) (nmole/sample) and all 
samples obtained at different passages and on different days. 
Western Blot: 1 x 106 PCSCs were plated on 12 well plates and allowed to grow for 24 hours. 
Medium was then replaced with serum-free medium and allowed to incubate for a further 24 
hours for serum-starving. Following serum starvation, PCSCs were exposed to 3µM C1P, 3µM 
ceramide, or 1:1 CFPAC conditioned:fresh DMEM. All treatments were delivered via serum-free 
DMEM. Treatments were allowed to incubate for 5, 10, or 30 minutes before the treatment was 
removed. Plates were placed on ice and washed 2x with ice-cold PBS. Ice-cold lysis buffer was 
added and allowed to incubate for 15 minutes under constant agitation. Each well was 
subsequently scraped before the lysates were harvested. Lysates were centrifuged at max speed 
(14,000 rpm) for 10 minutes. The supernatant was transferred to fresh 1.5ml tubes, LDS was 
added, and lysates were incubated at 70°C for 10 minutes before loading onto 12% Bis-Tris gels. 
Western blots were probed for CerK, p42/44 MAPK, and total MAPK. Alpha-tubulin was used 
as a loading control. 
Dynamic Light Scattering (DLS): CFPAC conditioned medium was collected, vesicles isolated, 
as described above and analyzed by DLS. Vesicles preparations were characterized on a Nano 
Series Zetasizer (zetasizer, Malvern Instruments, Southborough, MA) (DLS; He-Ne laser, 633 
  
nm; 173backscattered light detection). Performed at 25 C, each measurement represents 4 
unique preparations, 3 runs per preparation and a minimum of 12 measurements per run for a 
total of 144 measurements.   
Animal Studies: In accordance with the Institutional Animal Care and Use Committee (IACUC) 
at the Indiana University School of Medicine (South Bend, IN) animals were housed in a 
pathogen-free facility with access to food and water ad libitum. Survival studies were performed 
using female nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice as 
previously described (18, 19). Mice were intraperitoneally injected with AsPC-1 cells (0.75 x 
106), ASPC-1 (0.75 x 106), + PCSC cells (0.75 x 106): 1:1 ratio, ASPC-1 (0.75 x 106),  + PCSC 
cells (1.5 x 106): 1:2 ratio, or PCSC cells alone (0.75 x 106). Animals were euthanized when 
moribund according to predefined criteria (19). Animal survival was evaluated from the first day 
of injection until death. 
Confocal Microscopy: For imaging experiments, cells were seeded in Nunc Lab-Tek™ II 8-well 
imaging plates (Fisher Scientific) in growth medium, grown to ~70% confluency and treated 
with either TopFluor-C1P (C11 TopFluorCeramide-1-phosphate: Avanti Polar Lipids, Inc. 
#810270) or TopFluor-Ceramide  (C11 TopFluor Ceramide: Avanti Polar Lipids, Inc., 
#810262).   Lipid was prepared by adding the required amount of stock lipid into a glass vial and 
dried under a stream of N2. Lipid was re-suspended in ethanol:dodecane (98:2) (Wijesinghe et al., 
2009) to a concentration of 100 µM, followed by sonication for ten cycles of 10 s on, 10 s off, 
followed by incubation in 37°C for 20 minutes.  Lipids were added to cells in 8-well imaging 
plates to a final concentration of 1 µM.  Cells were image using confocal microscopy (Zeiss 
LSM 710) using an oil 630x 1.4 numerical aperture objective.  TopFluor excitation was at 488 
nm with emission measured using green fluorescent protein (GFP) settings from 510 to 600 nm.         
  
3. Results: 
Sphingolipid mediated PCSC migration is Ceramide-1-phosphate specific. Bioactive 
sphingolipids regulate hematopoietic stem cell proliferation and migration, however little is 
known regarding the impact of sphingolipids on pancreatic cancer stem cells. PDAC cell 
migration in vitro is modulated by CerK expression, a key mediator of ceramide phosphorylation 
to C1P (20), however C1P levels in PDAC cells have not been explored. Lipidomic analysis 
identified a marked increase in C1P species in pancreatic adenocarcinoma cells, CFPAC, as 
compared to PCSC cells.  Specifically, statistically significant increases were detected 
d18:1/18:0-C1P, d18:1/18:1-C1P, and d18:1/20:0-C1P in CFPAC versus PCSC (Figure 1). 
Although d18:1/16:0-C1P species was more highly expressed in CFPAC cells versus PCSC, it 
did not reach statistical significance. To determine PSCS cell responsiveness, C1P dosing known 
to mediate hematopoietic progenitor cell recruitment were explored (3, 21).  The impact of 
sphingolipids lipid-mediated cell migration was screened using a 3-dimensional (3D) compaction 
assay that measures cell-cell interactions and cellular rearrangement. A decreased diameter 
reflecting a more compact spheroid and enhanced migration. C1P enhanced PCSCs migration 
while other sphingolipid metabolites such as ceramide, sphingosine or sphingosine-1-phophate 
had no impact (Figure 2A,B). Increased compaction in response to C1P was specific to PCSC 
cells, as no other tested sphingolipids impacted sphere formation of the PDAC cell lines CFPAC, 
and Panc-1 cells (Figure 2C,D). Conventional two-dimensional migration study in form of a 
scratch assay confirmed C1P-specific mediation of PCSC migration (Figure 2E). Absence of 
Ki67 staining at the leading edge of the wound (Fig. 2F, white line denotes leading wound edge, 
white arrows define Ki67 positive cells) verified that cell migration, not proliferation, was 
responsible for wound closure. Consistent with these findings, C1P had no impact on PCSC or 
  
CFPAC cell proliferation (Figure 3A) while C1P induced MAPK phosphorylation with 
dominance of the p42MAPK isoform at 5 and 10 minutes in a time-dependent manner (Figure 
3B).  
C1P-enhanced PCSC adhesion is fibronectin specific. As cell migration is modulated in part by 
cell-cell mutual bonding and adhesive free energy, the impact of C1P on adhesion was explored. 
Although PCSC demonstrated a dose-dependent binding to FN, CL, and LA (Figure 4A,B, and C 
respectively), addition of C1P enhanced only PCSC FN-dependent adhesion (Figure 4A). 
Interestingly, C1P had no impact on PDAC adhesion to CL or LA (Figure 4D, E). PDAC cells 
did not adhere to FN.  
PCSC cells interact with PDAC in an in vivo peritoneal dissemination model and in an in vitro 
migration and activation. Although human PDAC tumor growth in an animal survival peritoneal 
dissemination model replicates the clinical progression of pancreatic cancer (18), little is known 
regarding the role of PCSC in disease progression. Using PDAC AsPC-1 cells alone or in 
combination with PCSC cells, tumor cells were injected intraperitoneally and animal survival 
was monitored within the groups from time of tumor cell injection. Median survival in AsPC-1 
cells alone was 40 days, consistent with previous studies (18, 22-24) (Figure 5A).  
Intraperitoneal PCSC cells resulted in no tumor growth and had no impact on survival at 80 days 
post-injection (Figure 5A, p < 0.0001 as compared to AsPC-1). However, mixed injection of 
PCSC and PDAC AsPC-1 cells at ratios of 1:1 or 1:2 markedly shortened survival [median 
survival at 29 and 33 days, respectively, a 33% (p=0.0006) or 28% (p=0.0023) decrease in 
survival] as compared to ASPC cells alone (40-day survival median time from tumor cell 
injection) suggesting a dynamic interaction between the two cell populations. In vitro analysis 
determined that CFPAC-conditioned medium as well as transwell co-culture of CFPAC cells 
  
with PCSC cells enhanced PCSC cell migration consistent with C1P (Figure 5B,C) as compared 
to vehicle or un-conditioned CFPAC medium (CFPAC Medium, Figure 5B). Similar to C1P, 
CFPAC-conditioned medium induced a rapid, robust MAPK phosphorylation, with dominance 
of the p42 MAPK isoform between 5 and 10 minutes of exposure (Figure 5D). Of note, CFPAC-
conditioned medium induced a greater effect on pMAPK and migration then C1P alone 
suggesting that other components are present in the conditioned medium that influence these 
parameters. 
C1P-rich PDAC secrete extracellular vesicles containing C1P whose peri-nuclear uptake by 
PCSC is consistent with that seen in TopFluor labeled C1P. Decreased survival by co-injection 
with PDAC/PCSC cells, increased MAPK phosphorylation in PCSC by conditioned PDAC 
medium, and enhanced migration of PCSC in PDAC transwell studies suggest that CFPAC cell 
secretion of a mediating factor promotes PCSC activation. Dynamic Light Scattering (DLS) 
analysis of extracellular vesicles isolated from serum-free CFPAC condition medium subjected 
to a sucrose gradient determined that 95.88% of the vesicles were 116nm + 3.5 SEM in size 
(Figure 6B). Lipidomic analysis determined that extracellular vesicles are C1P-containing with 
d18:1/18:0 as the predominant C1P species (Figure 6C). Consistent with secreted C1P-
containing vesicles, CFPAC cells in serum-free medium demonstrated an increase in the 
ceramide to ceramide-1-phosphate converting enzyme CERK as compared to normal medium 
(Figure 6D). CFPAC cells demonstrate minimal uptake of either fluorescent conjugated 
TopFluor-C1P or TopFluor-ceramide (Figure 6E,F). In contrast, PCSC cells have a marked peri-
nuclear focal uptake of TopFluor-C1P while minimal TopFluor-ceramide was transported 
intracellularly (Figure 6H,I respectively). Consistent with PCSC peri-nuclear uptake of 
  
TopFluor-C1P, CFPAC secreted extracellular vesicles surface-labeled with a fluorescent dye 
were taken up in a focal peri-nuclear pattern in PCSC cells (Figure 6J).  
  
4. Discussion: 
Cancer stem cells have a vital role in tumor initiation, growth, and metastasis. Identification of 
factors that modulate cancer stem cell recruitment is highly relevant to effectively treat 
aggressive and chemo-resistant pancreatic ductal adenocarcinomas.  Bioactive sphingolipids, 
sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P) have recently been identified as 
key mediators of stem cell mobilization, homing, metastasis, and activation (25). In this report, 
we demonstrate for the first time that C1P is a modulator of PCSC migration, and fibronectin 
specific based adhesion. Furthermore, we show that co-injection of PCSCs with PDAC cells 
reduce survival in a peritoneal dissemination animal model. Importantly, PDAC cells were 
identified as a source of C1P, conditioned medium from PDAC cells can simulate C1P-induced 
PCSC migration and signaling, and they secrete extracellular vesicles containing C1P. Taken 
together these studies support a role for PDAC modulation of PCSC through a C1P-mediated 
mechanism. 
Ceramide, long identified as a signaling molecule adept at regulating key cellular functions, 
effectively inhibits cell survival (26). In contrast, conversion of ceramide to ceramide-1-
phosphate through ceramide kinase (CerK) supports tissue regeneration, in part through 
endothelial progenitor cell chemoattraction. Elevated in damaged tissues following injury, a role 
for C1P in supporting tissue regeneration has been identified in the wound healing process. For 
example, elevation of C1P is associated with improved mobilization of circulating progenitor 
cells in cardiovascular disease (27), enhanced fibroblast migration in wound healing (28), and in 
spinal cord injury, C1P contributes to repair following injury (29, 30). In these studies, 
improvement in wound healing was in part attributed to C1P’s potential to recruit endothelial and 
neural stem cells. Other studies noted that progenitor cell responsiveness was sphingolipid 
  
specific as endothelial cell migration and regeneration are C1P specific (21) whereas both S1P 
and C1P impact multipotent stromal cell differentiation and proliferation (25). Similar processes 
could be employed by the tumor microenvironment to enhance growth and meet its metabolic 
demands. The role of C1P in tumor formation has not been extensively explored. However, a 
link between elevated S1P and C1P plasma levels in response to radio/chemotherapy in patients 
with rhabdomyosarcoma and the association of increased metastatic lesions suggests that 
sphingolipids facilitate a ‘prometastatic microenvironment’ (31).  
Interestingly, our observation that PDAC cells secrete C1P-containing vesicles supports the 
notion that C1P secretion could be an important mechanism of cell specific recruitment and 
activation of progenitor cells. In line with the concept that C1P promotes a ‘prometastatic 
microenvironment’, recent in vitro tumor cell invasion studies using PDAC cells determined that 
C1P impacts tumor cell mobility (20).  
In our studies, although other sphingolipids had minimal impact on the number of migrating 
PDAC cells, the magnitude of PCSC responsiveness specifically to C1P suggests it has the 
ability to recruit pancreatic cancer stem cells. Furthermore, our studies determined that PDAC 
cells are a rich source of C1P. In conjunction with elevated C1P levels in PDAC cells, CerK 
expression, a known enhancer in the conversion of ceramide to C1P is elevated in PDAC cells 
consistent with our findings has been previously reported (20). This is particularly important as 
CerK expression impacts recruitment of progenitor cell populations and tumor growth and when 
elevated in breast cancer was found to be associated with recurrence and tumor cell survival (32). 
Interestingly, our studies observed that during the stress of serum-free conditions, PDAC cells 
demonstrate an increase in CerK. Although this remains to be tested, this suggests that in PDAC 
cells, elevated CerK levels could contribute to the enzymatic conversion of ceramide to C1P and 
  
is a focus of our future studies. Previous studies have explored C1P levels in healthy and 
pathologic states to determine if there is an association between elevated C1P and disease 
progression. Although the levels of C1P found in serum and plasma of healthy individuals were 
(0.5M) (33) and isolates from irradiated mice demonstrate variable organ levels of C1P 
(2.12M/nM total phosphate in liver and 0.058 M/nM total phosphate in lung) (31), less is 
known regarding average C1P levels found in tumor cells. In this study, we determined that 
CFPAC cell C1P levels were species dependent. With the d18:1/16:0 C1P being the most 
prevalent species (Figure 1). These finding suggests that C1P and its biological influences are 
more complex than previously known. With C1P being released into the tumor 
microenvironment through secretion in extracellular vesicles, this C1P-rich tumor 
microenvironment could represent one method of PDAC cell mediated recruitment of the stem 
cells necessary to support the evolving tumor progression needs. Therefore, it is plausible that as 
the tumor needs escalate, one way to influence stem cell recruitment could be in part through 
CerK-mediated conversion of ceramide to C1P and subsequent release of C1P in extracellular 
vesicles into the tumor microenvironment. One such cell population is endothelial progenitor 
cells. Recent studies support a role for C1P-mediated recruitment of progenitor endothelial cells 
as a mechanism of promoting vascularization (21). In the context of ever-expanding tumor 
nutritional and metabolic requirements, release of C1P by tumor cells could represent one 
mechanism of tumor tissue recruitment of progenitor endothelial cell populations that can 
contribute to tumor vessel formation. Importantly, vessel growth is in part facilitated by adhesion 
of endothelial cells to fibronectin. Our studies determined that C1P-enhanced PCSC adhesion 
only to fibronectin while other extracellular matrix such as collagen and laminin were not 
impacted by C1P. These findings suggest that in the tumor microenvironment, C1P not only 
recruits progenitor CSC but also facilitates their adhesion. Previous studies explore the role of 
non-vesicular C1P following tissue damage that establishes a gradient responsible for stem cell 
recruitment (21). Our findings suggest that tumor cells secrete C1P-containing vesicles that 
facilitate stem cell migration in part through ERK activation.  Importantly, as vesicles have been 
associated with additional intraluminal cargo that can impact cellular function including 
microRNA, proteins, peptides, and nucleic acids, future studies are necessary to explore the role 
of C1P in the fate of extracellular vesicles and their cargo (34). Taken together, our findings 
suggest a mechanism that should be explored as a potential therapeutic target to reduce tumor 
progression.  
Our findings support a role for sphingolipid C1P-mediated PCSC migration, adhesion, and 
MAPK phosphorylation. Furthermore, we identified a potential C1P source as C1P rich PDAC 
cells release C1P-containing vesicles. Regulation of the enzymatic conversion in PDAC cells of 
ceramide to ceramide-1-phosphate could minimize stem cell recruitment and may represent a 
mechanism that could reduce pancreatic tumor progression. 
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Figure Legends: 
Figure 1: CFPAC cells are C1P rich. Subconfluent CFPAC and PCSC cells were sent for 
analysis of C1P. Lipidomic analysis of C1P normalized to the specific species standard curve, 
determined that C1P species d18:1/18:0-C1P (CFPAC: 41m  10SEM; PCSC:4.3m   
0.2SEM, * p<0.007) , d18:1/18:1-C1P (CFPAC: 48.3m  9SEM; PCSC:5.8m  0.7SEM, ** 
p=0.002), and d18:1/20:0-C1P (CFPAC: 18.8m  3.6SEM; PCSC:0.5m  0.1SEM, * 
p<0.007) were significantly increased in CFPAC versus PCSC (unpaired Student’s t-test, n= 
3/experiments performed on different cell passages harvested at different times and normalized 
to total cell number) (nomenclature: Sphingosine backbone of C1P is - 18:1). 
Figure 2: C1P mediated migration is selective to pancreatic cancer stem cells. Single cell 
suspensions of PCSC, CFPAC, and PANC1 in three-dimensional screening migration assay were 
assessed for aggregation at 48 hours with a decreased diameter reflecting a more compact 
spheroid and enhanced migration (measured as pixels). PCSC treated with C1P exhibited 
significant compaction (B, 3μM: 1.09 x 106  5.66 x 104 SEM pixels and 10μM: 9.01 x 105  2.1 
x 104 SEM pixels) (p < 0.0001)(unpaired Student’s t-test, n=10/condition/experiment performed 
a minimum of 5 times) as compared to vehicle (1.97 x 106  3.17 x 104 SEM pixels). 
Compaction was specific to C1P as ceramide (cer) (A, 10μM: 2.14 x 106  5.79 x 104 SEM pixel, 
B, 3μM: 1.88 x 106  10.8 x 104 SEM pixels and 10μM: 1.73 x 106  10.6 x 104 SEM pixels), 
S1P (A, 10μM: 2.25 x 106  4.8 x 104 SEM pixels) or sphingosine (Sph) (A, 10μM: 2.38 x 106  
2.5 x 104 SEM pixels) had no impact on PCSC aggregation. C1P had no impact on Panc1 or 
CFPAC cell aggregation (C, D respectively). Confluent monolayers subjected to in vitro scratch 
  
assay were assessed for wound closure at 24 hours. PCSC treated with C1P had a 41% (E, 
10μM: 41%  2.7 SEM closure)(p=0.005)(ANOVA with post-hoc comparison, 
n=3/condition/experiment performed a minimum of 5 occasions) as compared to vehicle (E, 26% 
 1.7 SEM closure) and ceramide (10μM: 25%  0.4 SEM closure). Ki67 immunofluorescence 
staining (Cy3) at wound leading edge (white dotted line) supports wound closure in C1P treated 
cells is predominately due to migration (F). C1P and ceramide had no impact on CFPAC wound 
closure (G). 
 
Figure 3: C1P had no impact on CSC or CFPAC proliferation, but does induce MAPK 
phosphorylation in CSC cells. Proliferation using WST in subconfluent CSC or CFPAC cells 
was not influenced by C1P (1-10μM) or ceramide (1-10μM) (A). Subconfluent PCSC cells were 
assessed for phosphorylation of MAPK overtime determined that C1P selectively induced 
significant phosphorylation as compared to ceramide (B, n=3, three different occasions, 
p=0.0003, Two-way ANOVA). 
 
Figure 4: C1P increases FN-mediated PCSC adhesion. Wells coated with fibronectin (FN, 1-
10μM), collagen (CL,1-10μM), laminin (LA, 1-10μM), or vehicle (CAPS) as indicated while 
some wells were dual-coated with C1P (10μM) or ceramide (10μM). PCSC or CFPAC cells were 
seeded on pre-coated plates and adherent cells identified by crystal violet staining. PCSC cells 
demonstrated dose-dependent adhesion to FN (A), CL (B) and LA (C). CFPAC cells were non-
adherent to FN (data not shown) but demonstrated a dose-dependent adhesion to CL (D). C1P 
significantly enhanced PCSC adhesion to 10 μM FN (A, 0.6145  0.0272 SEM) (p=0.04, 
  
n=4/condition/experiment performed a minimum of 4 occasions) as compared to 10 μM FN 
alone (0.4563 ± 0.0570 SEM) or ceramide + 10 μM FN (0.3440  0.0032 SEM). 
 
Figure 5: CSCs co-injected with AsPC-1 cells reduces animal survival while CFPAC 
conditioned medium and CFPAC in transwells increased CSC migration. Studies using 
AsPC-1 cells (0.75 x 106), AsPC-1 (0.75 x 106), + CSC cells (0.75 x 106), AsPC-1 (0.75 x 106),  
+ CSCs (1.5 x 106), or CSCs alone (0.75 x 106) were injected intraperitoneally into NOD/SCID 
mice. Survival from was noted from time of tumor cell injection. Statistical group differences in 
survival time were calculated using log rank testing (Mantel-Cox) with reduction in survival 
noted in combined injected cell populations PCSC / AsPC-1 (1:1- p=000.6 and 1:2- p =0.0023) 
as compared to AsPC-1 cells alone (A). Study was concluded on day 80 with no loss of CSC 
injected animals (p=0.0001, A) (n=6/group). Consistent with C1P enhanced migration (A, 
*p=0.0184, 45%  0.43 SEM), CSCs treated with CFPAC-conditioned medium (B, **p=0.0025, 
59%  2.5 SEM) significantly increased wound closure in CSC scratch assays as compared to 
unconditioned CFPAC medium (23%  1.1 SEM) or control medium (36%  2.2 SEM) (B, 
n=3/condition/experiment performed a minimum of 4 occasions). Transwell co-culture of 
CFPAC cells with wounded CSCs significantly enhanced wound closure (B,**p=0.471, 43%  
2.6 SEM) consistent with that seen with C1P (B,*p=0.0035, 46%  6.2 SEM) as compared to 
control (C, 19%  3.3 SEM) (n=4/condition/experiment performed a minimum of 3 occasions). 
CFPAC-conditioned medium induced a similar pattern of MAPK phosphorylation with 
densitometry analysis indicating a 5-fold increase in pMAPK (D, n=2,two different occasions, 
representative blot). 
  
 
Figure 6: Extracellular vesicles secreted in CFPAC-conditioned medium are rich in C1P 
and C1P uptake is peri-nuclear in progenitor cells and is similar to uptake of CFPAC 
secreted C1P-containing extracellular vesicles. The size of vesicles isolated using a sucrose 
gradient from CFPAC conditioned medium were assessed using Dynamic Light Scattering 
(DLS) where 95.88% were found to be 116nm  3.5 SEM in size while the remaining 4.125% 
were 4219nm  11.7 SEM (B) (n=4 unique preparations, 3 runs per preparation and a minimum 
of 12 measurements per run for a total of 144 measurements). Secreted vesicle isolates from 
serum-free (SF) CFPAC cells were noted to contain C1P species consistent with that seen in 
whole cell lysate (normalized to total phosphate: Pi, nmole/sample) (C). CFPAC cells in serum-
free (SF) medium by densitometry analysis have a 1.48 increase in CERK compared to cells in 
normal medium (N) (D, n=2, representative blot). TopFluor labeled ceramide and C1P lipid 
uptake in sub-confluent PCSC and CFPAC cells. PCSCs exhibit a marked increase in C1P 
uptake in the perinuclear region (I) as compared to CFPAC (F) or TopFluor-ceramide (H,E). 
Conditioned medium from CFPAC cells was collected; extracellular vesicles isolated and 
surfaced labeled (A, PKH26 red fluorescent dye) and added to subconfluent cells (n=3 on 
different occasions). Perinuclear uptake of extracellular vesicles was significantly greater in 
PCSCs (J) as compared to CFPAC cells (G) (G,J: DAPI staining denotes nucleus) (n=3 on 
different occasions). Scale bar: 10μm(E,F,H,I), 20μm(G,J). 
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Figure 1: CFPAC cells are C1P rich. Subconfluent CFPAC and PCSC cells were sent for analysis of 
C1P. Lipidomic analysis of C1P normalized to the specific isoforms standard curve, determined that 
C1P species d18:1/18:0-C1P (CFPAC: 41ρm ± 10SEM; PCSC:4.3ρm ±  0.2SEM, * p<0.007) , 
d18:1/18:1-C1P (CFPAC: 48.3ρm ± 9SEM; PCSC:5.8ρm ± 0.7SEM, ** p=0.002), and d18:1/20:0-C1P 
(CFPAC: 18.8ρm ± 3.6SEM; PCSC:0.5ρm ± 0.1SEM, * p<0.007) were significantly increased in CFPAC 
versus PCSC (unpaired Student’s t-test, n= 3/experiments performed on different cell passages harvested 
at different times and normalized to total cell number) (nomenclature: Sphingosine backbone of C1P is - 18:1).
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Figure 2: C1P mediated migration is selective to pancreatic cancer stem cells. Single cell suspensions of PCSC, 
CFPAC, and PANC1 in three-dimensional screening migration assay were assessed for aggregation at 48 hours 
with a decreased diameter reflecting a more compact spheroid and enhanced migration (measured as pixels). 
PCSC treated with C1P exhibited significant compaction (B, 3μM: 1.09 x 106 + 5.66 x 104 SEM pixels and 
10μM: 9.01 x 105 + 2.1 x 104 SEM pixels) (p < 0.0001) (unpaired Student’s t-test, n=10/condition/experiment 
performed a minimum of 5 times) as compared to vehicle (1.97 x 106 + 3.17 x 104 SEM pixels). Compaction was 
specific to C1P as ceramide (cer) (A, 10μM: 2.14 x 106 + 5.79 x 104 SEM pixel, B, 3μM: 1.88 x 106 + 10.8 x 104 SEM 
pixels and 10μM: 1.73 x 106 + 10.6 x 104 SEM pixels), S1P (A, 10μM: 2.25 x 106 + 4.8 x 104 SEM pixels) or 
sphingosine (Sph) (A, 10μM: 2.38 x 106 + 2.5 x 104 SEM pixels) had no impact on PCSC aggregation. C1P had no 
impact on Panc1 or CFPAC cell aggregation (C, D respectively). Confluent monolayers subjected to in vitro scratch 
assay were assessed for wound closure at 24 hours. PCSC treated with C1P had a 41% (E, 10μM: 41% + 2.7 SEM 
closure)(p=0.005)(ANOVA with post-hoc comparison, n=3/condition/experiment performed a minimum of 5 occasions) 
as compared to vehicle (E, 26% + 1.7 SEM closure) and ceramide (10μM: 25%+0.4 SEM closure). Ki67 immuno-
fluorescence staining (Cy3) at woundleading edge (white dotted line) supports wound closure in C1P treated cells is 
predominately due to migration (F). C1P and ceramide had no impact on CFPAC wound closure (G).
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Figure 3: C1P had no impact on CSC or CFPAC proliferation, but does induce MAPK phosphorylation in 
CSC cells. Proliferation using WST in subconfluent CSC or CFPAC cells was not influenced by C1P (1-10μM) 
or ceramide (1-10μM) (A). Subconfluent PCSC cells were assessed for phosphorylation of MAPK overtime 
determined that C1P selectively induced significant phosphorylation as compared to ceramide (B, n=3, three 
different occasions, p=0.0003, Two-way ANOVA).
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Figure 4: C1P increases FN-mediated PCSC adhesion. Wells coated with fibronectin (FN, 1-10μM), 
collagen (CL,1-10μM), laminin (LA, 1-10μM), or vehicle (CAPS) as indicated while some wells were 
dual-coated with C1P (10μM) or ceramide (10μM). PCSC or CFPAC cells were seeded on pre-coated 
plates and adherent cells identified by crystal violet staining. PCSC cells demonstrated dose-dependent 
adhesion to FN (A), CL (B) and LA (C). CFPAC cells were non-adherent to FN (data not shown) but 
demonstrated a dose-dependent adhesion to CL (D). C1P significantly enhanced PCSC adhesion to 
10 μM FN (A, 0.6145 + 0.0272 SEM) (p=0.04, n=4/condition/experiment performed a minimum of 4 
occasions) as compared to 10 μM FN alone (0.4563 ± 0.0570 SEM) or ceramide + 10 μM FN 
(0.3440 + 0.0032 SEM).
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Figure 5: CSCs co-injected with AsPC-1 cells reduces animal survival while CFPAC conditioned medium and CFPAC in 
transwells increased CSC migration. Studies using AsPC-1 cells (0.75 x 106), AsPC-1 (0.75 x 106), + CSC cells 
(0.75 x 106), AsPC-1 (0.75 x 106),  + CSCs (1.5 x 106), or CSCs alone (0.75 x 106) were injected intraperitoneally 
into NOD/SCID mice. Survival from was noted from time of tumor cell injection. Statistical group differences in survival 
time were calculated using log rank testing (Mantel-Cox) with reduction in survival noted in combined injected cell 
populations PCSC / AsPC-1 (1:1- p=000.6 and 1:2- p =0.0023) as compared to AsPC-1 cells alone (A). Study was 
concluded on day 80 with no loss of CSC injected animals (p=0.0001, A) (n=6/group). Consistent with C1P enhanced 
migration (A, *p=0.0184, 45%+ 0.43 SEM), CSCs treated with CFPAC-conditioned medium (B, **p=0.0025, 
59%+ 2.5 SEM) significantly increased wound closure in CSC scratch assays as compared to unconditioned CFPAC 
medium (23%+ 1.1 SEM) or control medium (36%+2.2 SEM) (B, n=3/condition/experiment performed a minimum 
of 4 occasions). Transwell co-culture of CFPAC cells with wounded CSCs significantly enhanced wound closure 
(B,**p=0.471, 43%+ 2.6 SEM) consistent with that seen with C1P (B,*p=0.0035, 46%+ 6.2 SEM) as compared to control 
(C, 19%+ 3.3 SEM) (n=4/condition/experiment performed a minimum of 3 occasions). CFPAC-conditioned medium induced 
a similar pattern of MAPK phosphorylation with densitometry analysis indicating a 5-fold increase in pMAPK (D, n=2,two 
different occasions, representative blot).
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Figure 6: Extracellular vesicles secreted in CFPAC-conditioned medium are rich in C1P and C1P uptake 
is peri-nuclear in progenitor cells and is similar to uptake of CFPAC secreted C1P-containing extracellular vesicles. 
The size of vesicles isolated using a sucrose gradient from CFPAC conditioned medium were assessed using Dynamic 
Light Scattering (DLS) where 95.88% were found to be 116nm ± 3.5 SEM in size while the remaining 4.125% were 
4219nm ± 11.7 SEM (B) (n=4 unique preparations, 3 runs per preparation and a minimum of 12 measurements per run 
for a total of 144 measurements). Secreted vesicle isolates from serum-free (SF) CFPAC cells were noted to contain C1P 
species consistent with that seen in whole cell lysate (normalized to total phosphate: Pi, nmole/sample) (C). CFPAC cells in 
serum-free (SF) medium by densitometry analysis have a 1.48 fold increase in CERK compared to cells in normal medium
(N) (D, n=2, representative blot). TopFluor labeled ceramide and C1P lipid uptake in sub-confluent PCSC and CFPAC cells. 
PCSCs exhibit a marked increase in C1P uptake in the perinuclear region (I) as compared to CFPAC (F) or TopFluor-ceramide 
(H,E). Conditioned medium from CFPAC cells was collected; extracellular vesicles isolated and surfaced labeled (A, PKH26 
red fluorescent dye) and added to subconfluent cells (n=3 on different occasions). Perinuclear uptake of extracellular 
vesicles was significantly greater in PCSCs (J) as compared to CFPAC cells (G) (G,J: DAPI staining denotes nucleus) 
(n=3 on different occasions). Scale bar: 10μm(E,F,H,I), 20μm(G,J).
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C1P rich PDAC cells release 
C1P-containing vesicles that 
impact migration and 
adhesion of PSCS cells.
